MedTrace Logo

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

NCT02205606 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 412

Last updated 2015-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of HCP1306 in patients with primary hypercholesterolemia.

Conditions

  • Primary Hypercholesterolemia

Interventions

DRUG

HGP0816 5mg

P.O.

DRUG

HGP0816 10mg

P.O.

DRUG

HGP0816 20mg

P.O.

DRUG

HCP1306 5/10mg

P.O.

DRUG

HCP1306 10/10mg

P.O.

DRUG

HCP1306 20/10mg

P.O.

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Hyo-soo Kim, MD, Ph.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-02-28
Completion
2015-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02205606 on ClinicalTrials.gov